Neurelis Receives FDA Orphan Drug Designation for NRL-1 in the Treatment of Acute Repetitive Seizures
Neurelis, Inc. (“Neurelis”) today announced receipt of Orphan Drug Designation from the FDA for their lead program, NRL-1 (intranasal diazepam) for pediatric, adolescent, and adult epilepsy patients who experience acute repetitive seizures. The FDA’s Orphan Drug Designation program provides orphan status to drugs intended for the safe and effective treatment of rare disorders that affect […]